XNAS · Healthcare · Biotechnology
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | Q1 2026 | 0.19 | 0.25 | +31.58% | $77.7M | ✅ Beat | -0.58% | +4.62% | — |
| 2026-02-26 | Q4 2025 | 0.21 | 0.26 | +23.81% | $77.1M | ✅ Beat | +3.19% | +5.51% | +2.15% |
| 2025-11-04 |
| Q3 2025 |
| 0.16 |
| 0.23 |
| +43.75% |
| $73.5M |
| ✅ Beat |
| — |
| — |
| — |
| 2025-07-31 | Q2 2025 | 0.16 | 0.16 | +0.00% | $70.0M | ➖ Inline | +4.75% | +23.63% | +29.69% |
| 2025-02-27 | Q4 2024 | -0.02 | 0.01 | +150.00% | $59.9M | ✅ Beat | +5.30% | +8.48% | +6.49% |
| 2024-11-07 | Q3 2024 | 0.01 | 0.10 | +900.00% | $67.8M | ✅ Beat | -0.24% | -0.12% | +9.47% |
| 2024-08-01 | Q2 2024 | 0.01 | 0.01 | +0.00% | $57.2M | ➖ Inline | -1.96% | -2.50% | +19.07% |
| 2024-05-02 | Q1 2024 | -0.14 | -0.03 | +78.57% | $50.3M | ✅ Beat | -1.35% | +0.00% | +3.67% |
Showing last 8 quarters.